武田制药(TAK)股吧_武田制药怎么样_分析讨论社区

列表
摘要

发新帖

发表新帖
问董秘
发起斗股

阅读	评论	标题	作者	最后更新
468	0	13家药企争抢比拉斯汀仿制药市场，江苏华阳制药率先过评	摩熵医药	11-15 03:34
385	0	看好中国市场，这些成果“上新”	赛诺菲资讯	11-08 10:55
412	0	搭乘进博会快车 “进博宝宝”茁壮成长	赛诺菲资讯	11-06 02:16
367	0	进博观察 \| 首日多款新品亮相：跨国医械企业迎高质量发展契机	美敦力资讯	11-05 09:13
279	0	武田制药创新基因疗法将于第七届进博会进行全球首展	武田制药资讯	11-05 11:07
1131	0	人民日报头版：以中国式现代化新进展为世界提供新机遇	武田制药资讯	11-05 08:03
335	0	续写共享未来美好篇章——写在第七届中国国际进口博览会开幕之际	罗克韦尔自动化资讯	11-05 05:59
1169	0	医疗界神仙打架，探营进博会“最卷”展区	赛诺菲资讯	11-04 08:11
126	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	10-31 06:39
118	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	10-31 06:32
114	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	10-31 06:26
1141	0	进博会前瞻｜共享全球机遇，今年跨国药械企业带来哪些首发首展新品？	赛诺菲资讯	10-30 04:29
1462	1	11家世界500强药企和全球十大医疗器械企业齐聚上海预订“最卷展区”	诺和诺德资讯	10-25 07:06
344	0	武田制药将在第七届进博会展示多领域创新成果	武田制药资讯	10-14 08:40
163	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	09-26 06:15
247	0	施耐德电气携手武田制药，共建生命科学行业绿色可持续未来	E药经理人	09-05 11:07
545	3	中国创新药的出路	医曜官方	08-23 07:58
740	2	逆势新高，血液肿瘤Biotech的巨头底色	瞪羚社	08-26 08:04
186	0	Report of proposed sale of securities	武田制药资讯	08-23 08:57
447	1	中国正成全球生物医药创新策源地——访武田制药全球高级副总裁、武田中国总裁单国洪	武田制药资讯	08-23 06:00
229	0	连续三天地量成交，A股新一轮的机会在哪？\| 第一财经采访桓睿天泽	桓睿天泽	08-19 10:23
332	1	亚洲最大药企，为何裁员一千多人？	iNews新知科技	08-08 07:26
664	0	全球裁员上千人、出售中国子公司跨国药企究竟怎么了？	武田制药资讯	08-05 01:44
277	0	武田制药计划在美裁员1000人；Zymeworks终止HER2双抗ADC开发	氨基观察	08-05 10:58
437	0	当医保收支形成“剪刀差”之后	氨基观察	08-05 10:58
383	0	武田制药据悉拟关闭美国加州研发中心并在美裁员1000人	武田制药资讯	08-02 05:32
178	0	[Amend] Statement of Beneficial Ownership by Certain Investors	武田制药资讯	07-31 09:02
218	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	07-31 06:29
322	0	日本占全球90%中药市场份额，比中国中药领先20年，谁告诉你的？	多肉话题君	07-15 07:39
211	0	Report of proposed sale of securities	武田制药资讯	07-10 08:11
164	0	Report of proposed sale of securities	武田制药资讯	07-10 08:02
206	0	Report of proposed sale of securities	武田制药资讯	07-10 07:57
201	0	Report of proposed sale of securities	武田制药资讯	07-10 07:57
161	0	Report of proposed sale of securities	武田制药资讯	07-10 07:47
203	0	Report of proposed sale of securities	武田制药资讯	07-10 07:47
204	0	Report of proposed sale of securities	武田制药资讯	07-10 07:36
210	0	Report of proposed sale of securities	武田制药资讯	07-10 07:36
205	0	Report of proposed sale of securities	武田制药资讯	07-10 07:36
210	0	Report of proposed sale of securities	武田制药资讯	07-10 07:26
212	0	Report of proposed sale of securities	武田制药资讯	07-10 07:26
207	0	Report of proposed sale of securities	武田制药资讯	07-10 07:26
212	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	07-10 06:28
158	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	07-09 06:27
203	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	07-06 12:30
166	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	07-02 06:48
215	0	医药智投丨武田制药药物交易风云：近年数据透视其战略布局新动向	医药智投	07-02 08:48
165	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	07-01 07:26
168	0	Prospectus [Rule 424(b)(2)]	武田制药资讯	06-28 08:37
125	0	Filing under Securities Act Rules 163/433 of free writing prospectuses	武田制药资讯	06-28 08:37
111	0	Prospectus [Rule 424(b)(5)]	武田制药资讯	06-27 06:54
112	0	Automatic shelf registration statement of securities of well-known seasoned iss	武田制药资讯	06-26 08:48
116	0	Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	武田制药资讯	06-26 06:42
118	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-26 06:19
113	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-26 06:18
793	0	武田制药用于治疗某些结肠直肠癌症的Fruzagla获得欧盟批准	武田制药资讯	06-22 04:07
179	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-17 07:01
224	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-11 07:01
247	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-10 06:25
220	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-07 06:13
217	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-07 06:13
231	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-03 06:54
222	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	06-03 06:52
246	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-29 09:18
238	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-29 09:17
245	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-29 09:17
236	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-29 09:16
258	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-21 06:18
816	1	最高可达22亿美元！拿下瑞士药企阿尔茨海默病疫苗，武田制药再战研发“死亡谷”	武田制药资讯	05-15 07:52
319	0	武田制药2023财年营收同比增长5.9%	武田制药资讯	05-14 08:21
1037	3	5月13日，武田制药(TAK.US)宣布引进ACImmune的阿尔茨海默症A疫苗	期待回本注销账户	05-14 09:20
285	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-09 06:21
270	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-09 06:20
262	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-09 06:20
261	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-09 06:20
260	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	05-09 06:20
302	0	武田制药称2024财年将产生1400亿日元的重组费用	武田制药资讯	05-09 03:13
255	0	Specialized disclosure report	武田制药资讯	04-25 06:20
251	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	04-19 06:28
251	0	Report of foreign issuer [Rules 13a-16 and 15d-16]	武田制药资讯	04-15 07:04
271	0	[Amend] General statement of acquisition of beneficial ownership	武田制药资讯	04-10 06:18

emytylist